Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease
Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease
复制标题
使用纳米微粒口服英夫利昔单抗治疗炎症性肠病
DOI：
10.1016/j.carbpol.2021.118556
复制
发表时间：
2021
影响因子：
11.2
通讯作者：
Yu Chaohui
中科院分区：
文献类型：
--
作者：
Li Xin;Yu Mengli;Zhu Zhuo;Lu Chao;Jin Meng;Rao Yuefeng;Zhao Qingwei;Lu Xiaoyang;Yu Chaohui
抗肿瘤坏死因子-α（anti-TNF-α）阻断剂，对炎症性肠病（IBD）的治疗已显示出很好的疗效。然而，全身暴露于它可能会导致相当大的安全性问题，由于减少抑制全身免疫反应和响应的抗药抗体的产生损失。因此，我们试图设计一种用于口服抗TNF-α抗体治疗IBD的靶向载体系统。在本研究中，我们开发了一种基于壳聚糖（CS）/羧甲基壳聚糖（CMC）和藻酸盐（Alg）的口服英夫利昔单抗（IFX）纳米微粒中的载药，其可以保护IFX免受胃肠道的恶劣环境的影响，并产生靶向药物递送到发炎的肠道。微载体可通过改善炎症和维持肠上皮屏障来减轻结肠炎。
The anti-tumor necrosis factor-α (anti-TNF-α) blocker, has shown great efficacy for the treatment of inflammatory bowel disease (IBD). However, systemic exposure to it can cause considerable safety problems due to reduced suppression of the systemic immune response and loss of response to the production of anti-drug antibodies. Thus, we try to devise a targeted vehicle system for oral administration of anti-TNF-α antibodies for the treatment of IBD. In the present study, we developed an oral Infliximab (IFX) loaded nano-in-microparticles, based on chitosan (CS)/carboxymethyl chitosan (CMC) and alginate (Alg), which could protect IFX from the harsh environment of the gastrointestinal tract and produce targeted drug delivery to the inflamed intestine.In vivostudies demonstrated that the IFX loaded nano-in-micro vehicle can alleviate colitis by ameliorating inflammation and maintaining the intestinal epithelial barrier.